Posterior Blepharitis Clinical Trial
Official title:
Study of the Effect of Oral Azithromycin on Posterior Blepharitis
One hundred patients with the diagnosis of posterior blepharitis based on history taking and
proper physical examinations by two experienced ophthalmologists will include in the study.
Patients will diagnose with posterior blepharitis if they score at least one in two symptoms
(based on a subjective grading scale) and two signs (based on an objective grading scale) of
posterior blepharitis according to study criteria. Patients will exclude if they have the
following criteria: age< 12 years old,history of previous ocular or lacrimal
surgery,previous usage of contact lenses,any history of ocular allergy,history of systemic
diseases with ocular involvement (except rosacea), history of usage of topical or systemic
antibiotic in the last month, pregnancy or lactating mothers, liver failure and any history
of sensitivity to cyclines.
Qualified patients then randomly receive oral azithromycin (2 of 250 mg capsules for the
first day and 250mg for the next 4 days) or oral doxycycline (100mg capsule every 12 hours
for one month) in a double-blinded fashion. each patients in both treatment groups will
accurately instruct to apply warm compress and eyelid scrubbing 2 times a day for 5 minutes
each in the treatment period. Symptoms and signs were recorded for each patient in two
treatment groups at baseline visit (before treatment) and then in the days 7, 31, 37 and 61
after treatment.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02952079 -
Comparison of BlephEx to MiBoflo as Treatment Options for Blepharitis
|
N/A | |
| Completed |
NCT04469998 -
Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction
|
Phase 2 | |
| Completed |
NCT00681109 -
Topical IL-1-Ra for Treatment of Posterior Blepharitis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01456780 -
Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
|
Phase 4 |